

Human OGN/Osteoglycin Protein

Cat. No. OGN-HM101

Description

Source	Recombinant Human OGN/Osteoglycin Protein is expressed from HEK293 with His tag at the C-terminus. It contains Pro21-Phe298.
Accession	P20774
Molecular Weight	The protein has a predicted MW of 32.83 kDa. Due to glycosylation, the protein migrates to 45-60 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 1EU per µg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE

Formulation and Storage


Formulation	Lyophilized from 0.22 µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

Osteoglycin (OGN, a.k.a. mimecan) belongs to cluster III of the small leucine-rich proteoglycans (SLRP) of the extracellular matrix (ECM). In vertebrates OGN is a characteristic ECM protein of bone. The function of OGN has mainly been studied in mammals in which it regulates collagen fibrillogenesis, the efficiency of which is increased when it is processed by BMP-1/Tolloid-like metalloproteinases. OGN has a role in wound healing in the cornea, in atherosclerotic lesions and modulates myocardial integrity and remodelling. In addition, OGN enhances the neurite outgrowth promoted by insulin-like growth factor-2 and IGF binding protein-2.

Assay Data

Bis-Tris PAGE



Human OGN on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.